Esperion Reports First Quarter 2023 Financial Results
09 mai 2023 07h00 HE
|
Esperion Therapeutics, Inc.
– U.S. Net Product Revenue Grew Approximately 27% Y/Y to $17.0 Million – – Retail Prescription Equivalents Grew 15% Y/Y; New to Brand Prescriptions Grew 56% Q/Q – – Strengthened Capital Position...
Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9
04 mai 2023 08h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 04, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that it has retained Gibson Dunn to vindicate its contractual rights against Daiichi Sankyo Europe (“DSE”)...
Esperion to Participate in JMP Securities Life Sciences Conference
01 mai 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 01, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will participate in a fireside chat at JMP...
Esperion to Participate in Bank of America Securities 2023 Health Care Conference
27 avr. 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 27, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will host a fireside chat at Bank of America...
Esperion to Report First Quarter 2023 Financial Results May 9, 2023
25 avr. 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 25, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report first quarter 2023 financial results before the open of the U.S. financial markets on...
Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC
19 avr. 2023 08h42 HE
|
Esperion Therapeutics, Inc.
– Performance-Based Agreement Provides for Currax’s 72 Sales Representatives to Detail Esperion’s Products – – Reinforces Esperion’s Focus on Driving Persistent Growth By More Than Doubling Sales...
Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference
03 avr. 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 03, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will host a fireside chat at Needham’s 22nd...
Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
22 mars 2023 16h15 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 22, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”) today announced the closing of its previously announced registered direct offering of an...
Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
20 mars 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 20, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced that it has entered into a definitive agreement with healthcare-focused...
International Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular Risk
08 mars 2023 08h00 HE
|
Esperion Therapeutics, Inc.
– International Lipid Expert Group Recommends Earlier Utilization of Bempedoic Acid in Both Secondary Prevention Patients As Well As in Patients with Partial or Complete Statin Intolerance – ...